This article unpacks the architecture, applications, and future trajectory of the X Pharma Series, explaining why major investment firms and research institutions are betting heavily on this modular approach to drug design.

Patient 433—a 58-year-old former truck driver—had begun writing long, obsessive manifestos about a “city beneath the city” where “the sleepless ones wait.” His handwriting had shifted from block capitals to an elegant, flowing script he’d never learned.

We can expect to see several extensions in the next 24 months: